Search results
Added:
3 years ago
Cardiovascular disease (CVD) is the most common cause of death worldwide.1 With an estimated 7.6 million global deaths due to coronary heart disease in 2005,2 the size of the burden placed on society cannot be understated. Acute myocardial infarction (AMI), the classic ‘heart attack,’ will be the classification given to many of these deaths. In its most life-threatening form, AMI is identified…
View more
Added:
2 years ago
In this short interview from our coverage of the ACC.22 late-breaking trials, Dr Pim van der Harst and Dr Marie-Sophie de Koning (University Medical Center Groningen, NL) discuss the data from the GIPS-IV trial which investigates the safety and efficacy of the hydrogen sulfide (H2S) donor sodium thiosulfate (STS) in patients presenting with ST-segment elevation myocardial infarction (STEMI) …
View more
Foreword
Added:
3 years ago
Article
Added:
3 years ago
Heart disease remains the leading cause of death in the US, with ischemic heart disease comprising almost half of these deaths based on the most recent 2013 mortality data.1 While there have been reports of declining rates of acute myocardial infarction (AMI) from various registries and Medicare beneficiary reports, coronary heart disease remained the underlying cause of death in one out of seven…
View more
Added:
3 years ago
The use of percutaneous coronary intervention (PCI) for coronary artery revascularization has grown considerably since the first balloon angioplasty in 1977. Improvements in equipment and drug therapies plus the development of coronary artery stents have all contributed to the growth of PCI as an alternative to surgical revascularization. Compared with the early days of balloon angioplasty, when…
View more
Added:
3 years ago
Effective translation of reperfusion therapy to mortality reductions in ST-segment elevation myocardial infarction (STEMI) remains both time-critical in its implementation and dependent on optimal antithrombotic therapy. Innumerable clinical studies have explored several antithrombin and antiplatelet therapies in the immediate management of STEMI. With the wide array of the therapies now…
View more
Added:
3 years ago
Hospital readmissions contribute significant clinical and economic burden to patients and payers.1 Nearly 20 % of Medicare patients are readmitted to the hospital within 30 days of discharge, with heart failure listed as the most common reason for readmission.2 Based on a more than twofold variation in institutional readmission rates adjusted for patient clinical characteristics,3 preventable…
View more
Added:
3 years ago
Coronary artery disease (CAD), the most common cause of morbidity and mortality in the US, is frequently identified by coronary angiography. Decisions for treatment are often based on angiography alone, absent other clinical indicators for intervention. However, by angiography alone, conventional wisdom has suggested that a coronary stenosis is significant if there is at least a 50 % diameter…
View more
Added:
3 years ago
Hospital to Home (H2H) is a national quality improvement initiative of the American College of Cardiology (ACC) and the Institute for Healthcare Improvement (IHI). It builds on the success of the ACC Door-to-Balloon Alliance for Quality and the IHI 100K Lives and 5 Million Lives campaigns. The goal of the H2H initiative is to reduce 30-day all-cause readmission rates for patients discharged with…
View more
Added:
3 years ago
Cardiologists in general are strong advocates of evidence-based medicine, due to the critical nature of ischemic heart disease in patients. The use of up-to-date scientific evidence from research is paramount as the basis for making many medical decisions. There are three major advantages to using this approach. First, it offers some of the most objective ways to determine and maintain consistent…
View more
